In this issue:
Updated Australian transplant guidelines
Dexamethasone-sparing regimen prolongs PFS in frail patients
Sequential bispecific–CAR-T approach feasible for RR disease
Tocilizumab prophylaxis mitigates CRS in patients undergoing bispecific treatment
Cilta-cel bests real-world treatments for lenalidomide-refractory disease
European experts deem outpatient bispecific treatment feasible
Daratumumab-lenalidomide maintenance beneficial regardless of risk status
Hybrid modality whole-body PET/MRI may aid identification of high-risk SMM
Please login below to download this issue (PDF)